These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 15996972

  • 1. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A, Bloch M, Carr A, Amin J, Mallon PW, Ray J, Marriott D, Cooper DA, Emery S.
    J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
    [Abstract] [Full Text] [Related]

  • 2. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E, Delaugerre C, Teglas JP, Jullien V, Tréluyer JM, Veber F, Rouzioux C, Blanche S.
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [Abstract] [Full Text] [Related]

  • 5. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.
    Antivir Ther; 2006 Sep; 11(4):421-9. PubMed ID: 16856615
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group.
    Clin Infect Dis; 2007 Jun 01; 44(11):1484-92. PubMed ID: 17479947
    [Abstract] [Full Text] [Related]

  • 7. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
    Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD.
    Ther Drug Monit; 2007 Oct 01; 29(5):560-5. PubMed ID: 17898644
    [Abstract] [Full Text] [Related]

  • 8. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.
    HIV Med; 2010 May 01; 11(5):326-33. PubMed ID: 20070407
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM, van de Ende ME, Kroon FP, Lunel FV, Koopmans PP, Gras L, de Wolf F, Burger DM.
    J Antimicrob Chemother; 2007 Oct 01; 60(4):897-900. PubMed ID: 17704117
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
    Sahloff EG, Duggan JM.
    Ann Pharmacother; 2006 Oct 01; 40(10):1731-6. PubMed ID: 16968825
    [Abstract] [Full Text] [Related]

  • 11. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.
    AIDS; 2007 Nov 30; 21(18):2409-15. PubMed ID: 18025877
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S, De Luca A, Villani P, Bacarelli A, Ragazzoni E, Regazzi M, Cauda R, Navarra P.
    HIV Med; 2008 Apr 30; 9(4):239-45. PubMed ID: 18366448
    [Abstract] [Full Text] [Related]

  • 16. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
    Naeger LK, Struble KA.
    AIDS; 2006 Apr 04; 20(6):847-53. PubMed ID: 16549968
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.
    J Antimicrob Chemother; 2008 Sep 04; 62(3):579-82. PubMed ID: 18477709
    [Abstract] [Full Text] [Related]

  • 19. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH, Nassar N.
    Int J STD AIDS; 2008 Aug 04; 19(8):561-2. PubMed ID: 18663047
    [Abstract] [Full Text] [Related]

  • 20. Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.
    Crutchley RD, Ma Q, Sulaiman A, Hochreitter J, Morse GD.
    J Pharm Pract; 2011 Apr 04; 24(2):216-22. PubMed ID: 21712217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.